Evidence map›Paper›PMID 39821757›Full record

ArticleInvestigational new drugs2025

Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.

Marta Banchi, Maria Christina Cox, Arianna Bandini, Paola Orlandi, Costanza Tacchi, Fabio Stefanelli, Silvio Chericoni, Guido Bocci

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Banchi *Dipartimento Di Ricerca Traslazionale E Delle Nuove Tecnologie in Medicina E Chirurgia, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy. m.banchi@studenti.unipi.it.ORCID 0000-0003-0672-2066
Maria Christina Cox *Unità Di Ematologia, Fondazione Policlinico Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Arianna BandiniDipartimento Di Ricerca Traslazionale E Delle Nuove Tecnologie in Medicina E Chirurgia, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.
Paola OrlandiDipartimento Di Medicina Clinica E Sperimentale, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.
Costanza TacchiDipartimento Di Ricerca Traslazionale E Delle Nuove Tecnologie in Medicina E Chirurgia, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.
Fabio StefanelliDipartimento Di Patologia Chirurgica, Medica, Molecolare e Dell'Area Critica, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.
Silvio ChericoniDipartimento Di Patologia Chirurgica, Medica, Molecolare e Dell'Area Critica, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.
Guido BocciDipartimento Di Ricerca Traslazionale E Delle Nuove Tecnologie in Medicina E Chirurgia, Università Di Pisa, Via Savi 10, 56126, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous T-cell lymphomas (CTCLs) are a rare and heterogeneous subset of skin-localized, non-Hodgkin lymphomas. Our aim was to evaluate the in vitro antitumor activity of the multi-kinase inhibitor linifanib, either alone or in combination with metronomic vinorelbine (mVNR) or etoposide (mETO), on CTCL cells. In vitro proliferation assay and Luminex analysis showed that long-term, daily exposure of linifanib significantly inhibited the proliferation of the human CTCL cell line HH, in a concentration-dependent manner (IC

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsIndazolesLymphoma, T-Cell, CutaneousPhenylurea CompoundsProto-Oncogene Proteins c-aktSkin NeoplasmsTOR Serine-Threonine KinasesAdministration, MetronomicCell Line, TumorCell ProliferationDrug SynergismEtoposideHumansSignal TransductionVinblastineAntineoplastic AgentsEtoposideIndazoleslinifanibMTOR protein, humanPhenylurea CompoundsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesVinblastineVinorelbineCutaneous T-cell lymphomaEtoposideLinifanibMetronomic chemotherapyVinorelbine

Identifiers

PMID39821757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.